EGFR and non-small cell lung carcinoma: Interestingly, osimertinib also exhibited a higher therapeutic efficacy compared to that of standard EGFR-TKIs (gefitinib or erlotinib) in the first-line treatment of EGFR mutation-positive (with exon 19 deletion or the L858R mutation, but no T790M mutation) advanced NSCLC patients [54].